Study guide
Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization
EBP-EAP Examination in Paediatrics Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding
EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)
2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity
Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol
3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections
Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening
4 Chapter 4: Acute Paediatric Emergencies & Critical Care
EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination
5 Chapter 5: Paediatric Respiratory Medicine
Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations
6 Chapter 6: Paediatric Cardiology
Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever
7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition
Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure
8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance
Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management
9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism
Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)
10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health
Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy
11 Chapter 11: Paediatric Haematology & Oncology
Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia
12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy
Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules
13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions
The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia
14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics
Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics
15 Chapter 15: Paediatric Ophthalmology & ENT Disorders
Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions
16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health
Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance
17 Chapter 17: Adolescent Medicine & Healthcare Transition
Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition
18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics
Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics
19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine
Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy
Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization
Key Takeaways Explain This Topic AI
The atopic march describes the developmental progression initiated by epidermal barrier disruption—predominantly driven by loss-of-function FLG (filaggrin) mutations—leading to epicutaneous allergen sensitization, Th2 cytokine skewing (IL-4, IL-5, IL-13), and the sequential emergence of atopic dermatitis, food allergy, allergic rhinitis, and asthma.
Foundational management of atopic dermatitis mandates liberal, daily application of soap-free emollient moisturizers (250 to 500 g/week) combined with targeted topical corticosteroids during inflammatory flares; eczema herpeticum represents a dermatological emergency demanding immediate systemic aciclovir therapy.
Food allergy is dichotomized into IgE-mediated (rapid onset <2 hours, risk of life-threatening anaphylaxis, assessed via skin prick testing and serum allergen-specific IgE) and non-IgE-mediated entities (delayed gastrointestinal syndromes including proctocolitis and FPIES, diagnosed via empirical dietary exclusion and diagnostic challenge).
Cow's-milk and hen's-egg allergies frequently resolve during childhood, but timing varies; well-cooked-egg allergy resolves in about two-thirds by age 6, and raw-egg tolerance may develop later. Peanut, tree-nut and seafood allergies usually persist.
Oral immunotherapy (OIT) elevates the threshold of clinical reactivity to reduce risk from accidental dietary exposure through strict daily antigen administration; however, it does not reliably induce permanent immunological tolerance and carries ongoing risks of systemic allergic reactions.
Last updated: November 2026
Pediatric Allergy, Atopic Dermatitis, Food Hypersensitivity, and Desensitization
Allergic diseases represent the most prevalent group of chronic non-communicable disorders in European pediatric populations. Understanding the cellular immunopathology of epithelial barrier dysfunction, differentiating immediate IgE-mediated hypersensitivity from delayed non-IgE cellular responses, and executing structured escalation pathways in eczema and food allergy are core competencies for pediatric specialists.
The Atopic March: Epithelial Barrier Failure and Th2 Skewing
The atopic march describes the characteristic chronological progression of atopic manifestations during infancy and childhood. The classical sequence begins with atopic dermatitis (eczema) in early infancy, followed sequentially by IgE-mediated food allergy , allergic rhinitis , and bronchial asthma in late childhood and adolescence. [Genetic Susceptibility: FLG Mutations]
- |
- Stratum Corneum Barrier Breakdown
- Transepidermal Water Loss (TEWL)
- Epicutaneous Allergen Penetration
- |
- Epithelial Keratinocyte Alarmins
- TSLP, Interleukin-33, Interleukin-25
- |
- Dendritic Cell Priming & Polarization
- |
- Th2 & ILC2 Lymphocyte Skewing
- +----------------------+----------------------+
- | | |
- Interleukin-4 Interleukin-5 Interleukin-31
- & Interleukin-13 | |
- | Eosinophil Activation Severe Pruritus
- B-Cell IgE Class & Tissue Damage ('The Itch that Rashes')
- Switching
- |
- v
- [Sequential Clinical Evolution: The Atopic March]
- 1. Atopic Dermatitis (Infancy: Extensor / Cheeks)
- 2. IgE Food Allergy (4-12 Months: Milk, Egg, Peanut)
- 3. Allergic Rhinitis (Preschool / Early School Age)
- 4. Allergic Asthma (School Age / Adolescence)
- Molecular Pathogenesis
Epidermal Barrier Breakdown : Loss-of-function mutations in the gene encoding filaggrin ( FLG ) on chromosome 1q21 are the strongest known genetic predisposing factor for atopic dermatitis. Filaggrin is an essential structural protein that aggregates keratin intermediate filaments within stratum corneum corneocytes and breaks down into natural moisturizing factors (NMF), which maintain skin hydration and an acidic barrier pH ( 4.5 – 5.5 4.5\text{–}5.5 4.5 – 5.5 ). Filaggrin deficiency produces microscopic intercellular fissures, increased transepidermal water loss (TEWL) , and enables foreign environmental allergens (house dust mite, peanut proteins, animal dander) to penetrate deep into the dermis.
Alarmin Release : Damaged keratinocytes release epithelial alarmins, including Thymic Stromal Lymphopoietin (TSLP) , Interleukin-33 (IL-33) , and Interleukin-25 (IL-25) .
Th2 Lymphocyte Skewing : Alarmins instruct dermal dendritic cells to drive the differentiation of naive CD4+ T helper cells into Th2 lymphocytes and activate type 2 innate lymphoid cells (ILC2s). Th2 cells secrete signature type 2 cytokines:
IL-4 and IL-13 : Drive B-lymphocyte immunoglobulin class-switching to allergen-specific IgE ; downregulate filaggrin synthesis, creating a self-amplifying vicious cycle.
IL-5 : Promotes eosinophil differentiation, activation, and mucosal recruitment.
IL-31 : Binds neuro-receptors on cutaneous sensory nerves, triggering intractable, neurogenic pruritus ('the itch that rashes'). Scratching mechanically damages the stratum corneum further, inducing secondary bacterial colonization by Staphylococcus aureus .
Atopic Dermatitis (Eczema): Age-Specific Phenotypes
Atopic dermatitis presents with distinct morphological distributions that evolve as the child develops motor capabilities:
Infantile Stage (<2 years) : Characterized by acute, weeping, exudative, crusted erythematous papules and plaques. Primarily involves the facial cheeks, forehead, scalp, and the extensor surfaces of the limbs (reflecting crawling trauma). The napkin/diaper area is characteristically spared , because the occlusive, humid environment within the diaper prevents stratum corneum drying.
Childhood Stage (2 to 12 years) : Characterized by chronic, subacute, excoriated, lichenified plaques localized predominantly within flexural creases : antecubital fossae, popliteal fossae, anterior neck, flexor wrists, and ankles. Lichenification (thickening of the skin with accentuated skin markings) results from chronic repetitive scratching.
Adolescent Stage (>12 years) : Involves flexural folds, the face, retroauricular regions, neck, and hands, frequently accompanied by severe periorbital dermatitis and infraorbital Dennie-Morgan folds.
- The Evidence-Based Management Ladder [Step 4: Severe Refractory Disease]
- Targeted Biologics: Dupilumab (anti-IL-4R-alpha, ages >=6 mo)
- Systemic Immunosuppression: Ciclosporin, Methotrexate
- Phototherapy (Narrowband UVB)
- ^
- |
- [Step 3: Moderate-to-Severe Disease]
- Potent Topical Corticosteroids (Short Burst)
- Topical Calcineurin Inhibitors (Tacrolimus / Pimecrolimus)
- Proactive Maintenance Therapy (Twice-Weekly TCS to Flare Sites)
- ^
- |
- [Step 2: Mild-to-Moderate Flares]
- Mild-to-Moderate Topical Corticosteroids (Hydrocortisone 1% on Face/Folds)
- Treat Secondary Bacterial Impetiginization (Flucloxacillin)
- ^
- |
- [Step 1: Universal Foundational Therapy for ALL Patients]
- Liberal, Frequent Emollient Therapy (250 to 500 g/week in Children)
- Apply Post-Bathing ('Soak and Seal' within 3 minutes)
- Strict Avoidance of Soaps / Detergents (Use Soap-Free Cleansers)
Foundational Barrier Restoration (Emollients) : The single most vital continuous intervention. Ointments (greasier, preservative-free) or thick creams must be applied liberally, smoothing down in the direction of hair growth. Pediatric guidelines recommend 250 to 500 g of emollient per week in children. Bathing should be brief in lukewarm water, using soap-free wash substitutes; emollients must be applied immediately post-bath ('soak and seal').
Topical Corticosteroids (TCS) : First-line pharmacological therapy during active inflammatory flare-ups.
Potency Matching : Mild TCS (hydrocortisone 1%) for the face, eyelids, neck, and skin flexures/diaper area to avert cutaneous atrophy and telangiectasia; Moderate (clobetasone butyrate 0.05%) or Potent (betamethasone valerate 0.1%, mometasone furoate 0.1%) for lichenified trunk and extremity plaques.
Dosing Guide (The Fingertip Unit / FTU) : One FTU is the quantity of cream or ointment expressed from a 5 mm nozzle tube from the distal skin crease to the tip of an adult index finger (approximately 0.5 g). One FTU covers an anatomical skin area equivalent to two adult handprints .
Proactive Maintenance : In children with frequent recurrent flares, applying a moderate-potency TCS or TCI twice weekly (weekend therapy) to previously affected quiescent sites dramatically reduces recurrence rates compared to reactive treatment alone.
Topical Calcineurin Inhibitors (TCI) : Tacrolimus 0.03% ointment (licensed ≥ 2 \ge 2 ≥ 2 years) and Pimecrolimus 1% cream . TCIs inhibit calcineurin, blocking nuclear factor of activated T cells (NFAT) dephosphorylation and T-cell cytokine gene transcription. TCIs provide targeted anti-inflammatory efficacy without causing epidermal atrophy, skin thinning, striae, or glaucoma , rendering them the steroid-sparing agents of choice for delicate anatomical zones (face, eyelids, neck, perioral skin).
Systemic Targeted Biologics : Dupilumab , a fully human monoclonal antibody directed against the IL-4 receptor alpha subunit (IL-4R α \alpha α ) —thereby blocking dual intracellular signaling of both IL-4 and IL-13—is approved in Europe for pediatric patients aged 6 months and older with severe, refractory atopic dermatitis.
Eczema Herpeticum (Kaposi's Varicelliform Eruption)
Eczema herpeticum is a life-threatening dermatological emergency caused by secondary dissemination of Herpes Simplex Virus (HSV-1 or HSV-2) across skin compromised by atopic dermatitis.
Clinical Presentation : Sudden, explosive onset of painful, monomorphic, dome-shaped, clustered umbilicated vesicles that rapidly rupture to leave characteristic 'punched-out' round erosions with hemorrhagic crusts . Lesions predominate on the face and neck. The eruption is accompanied by high fever, severe malaise, irritability, and painful regional lymphadenopathy.
Sight-Threatening Complication : Involvement of the periorbital skin carries high risk of herpetic keratoconjunctivitis, dendritic corneal ulceration, corneal scarring, and permanent blindness.
Emergency Management : Immediate initiation of systemic Aciclovir (oral aciclovir for mild, early cases; intravenous aciclovir 10–15 mg/kg every 8 hours for severe, generalized, or ophthalmic presentations). Clinicians must never delay aciclovir while awaiting viral PCR swab results . Flucloxacillin is frequently co-administered to cover secondary S. aureus superinfection. Urgent ophthalmology consultation is mandatory if lesions are within the periorbital zone.
Caution
In a child with atopic dermatitis who presents with an acute outbreak of grouped, punched-out erosions, high fever, and malaise, suspect Eczema Herpeticum . Do not prescribe topical corticosteroids alone, which accelerate viral dissemination, and immediately initiate systemic Aciclovir .
Food Hypersensitivity: IgE-Mediated versus Non-IgE-Mediated
Paediatric adverse food reactions are divided into IgE-mediated and non-IgE-mediated allergic disorders based on underlying immunopathological mechanisms:
Clinical Parameter IgE-Mediated Food Allergy Non-IgE-Mediated Food Allergy
Onset of Symptoms Rapid : Within seconds to minutes, always < 2 hours <2\text{ hours} < 2 hours Delayed : Several hours to days (typically 2 to 48 hours)
Immunopathology Specific IgE cross-linking on mast cells → \rightarrow → Histamine & tryptase release T-cell mediated, eosinophilic, and cytokine-driven inflammation
Cutaneous Manifestations Acute urticaria (wheals), pruritus, flushing, angioedema (lips/eyes) Eczema exacerbation, delayed maculopapular rash (variable)
Respiratory / Systemic Rhinorrhea, bronchospasm, stridor, anaphylactic shock No typical IgE-type wheeze, stridor or anaphylaxis; FPIES can cause marked lethargy, hypotension and shock
Gastrointestinal Features Acute vomiting, crampy abdominal pain, immediate diarrhea Chronic diarrhea, blood/mucus in stool, malabsorption, failure to thrive
Signature Syndromes Immediate Food Anaphylaxis; Pollen Food Allergy Syndrome (PFAS) FPIP (Proctocolitis), FPIE (Enteropathy), FPIES (Enterocolitis)
Diagnostic Tests Skin Prick Test (SPT ≥ 3 mm \ge 3\text{ mm} ≥ 3 mm ) , Serum specific IgE (sIgE) Negative SPT and sIgE ; diagnostic trial of allergen exclusion and re-challenge
Gold Standard Double-Blind Placebo-Controlled Food Challenge (DBPCFC) Diagnostic elimination (2–4 weeks) followed by planned re-challenge
Clinical Entities of Non-IgE-Mediated Food Allergy
Food Protein-Induced Allergic Proctocolitis (FPIAP) : Consider this non-IgE condition in a thriving young infant with painless blood streaks and mucus in otherwise normal stools , after excluding other causes such as an anal fissure. Continue breastfeeding with a 2–4-week trial of maternal cow's-milk exclusion , or use extensively hydrolyzed formula if formula-fed, then arrange planned reintroduction to confirm the diagnosis. Consider additional food exclusion only if symptoms persist, with dietary advice. Prognosis is generally favorable: tolerance develops during infancy or early childhood, with periodic reassessment rather than a guaranteed resolution by the first birthday.
Food Protein-Induced Enteropathy (FPIE) : Presents in infants under 9 months with chronic diarrhea, malabsorption, intermittent vomiting, villous blunting on jejunal biopsy, and significant faltering growth (failure to thrive) . Commonest triggers are cow's milk and soy.
Food Protein-Induced Enterocolitis Syndrome (FPIES) : Severe, non-IgE, cell-mediated disorder. Typically triggered by cow's milk, soy, rice, or oats. Presents with profuse, repetitive projectile vomiting commencing precisely 1 to 4 hours after ingestion , accompanied by severe lethargy, marked pallor, hypothermia, and abdominal distension. In 15% of acute episodes, severe dehydration and hypovolaemic shock supervene. Cutaneous (hives) and respiratory (wheeze) signs are absent. Severe episodes require IV isotonic crystalloid resuscitation ( 20 mL/kg 20\text{ mL/kg} 20 mL/kg , reassessing and repeating as needed); ondansetron is an adjunct from 6 months. Mild episodes may need only oral rehydration.
Major Food Allergens and Natural History
Over 90% of childhood food allergies are caused by the 'Big Eight' allergens: cow's milk, hen's egg, peanut, tree nuts (cashew, walnut, almond, hazelnut), wheat, soy, fish, and shellfish .
High Resolution Rates (Outgrown) :
Cow's Milk & Hen's Egg : Both frequently resolve during childhood, with variable timing. Allergy to well-cooked egg resolves in about two-thirds by age 6 years ; tolerance to raw egg may develop later. Reassess each child's tolerance individually.
The Dietary Matrix (The Milk and Egg Ladders) : Heat denatures conformational epitopes on milk and egg proteins. Up to 70% of milk- and egg-allergic children tolerate extensively heated / baked forms (e.g., muffins, cookies). Ingesting baked milk/egg accelerates immunological tolerance, allowing structured step-wise reintroduction along the validated 'Milk Ladder' or 'Egg Ladder'.
High Persistence Rates (Lifelong) :
Peanut, Tree Nuts, and Seafood : Unfavorable natural history. Spontaneous outgrowing occurs in fewer than 15% to 20% of children; over 80% to 85% persist into adult life with lifelong risk of severe anaphylaxis.
Diagnostic Interpretation: Sensitization versus Clinical Allergy
Skin Prick Testing (SPT) and serum allergen-specific IgE (sIgE) quantify immunological sensitization , which is NOT synonymous with clinical allergy :
An SPT wheal diameter ≥ 3 mm \ge 3\text{ mm} ≥ 3 mm greater than the negative saline control is technically positive.
A positive test merely demonstrates the presence of circulating IgE capable of binding the allergen.
Clinical allergy requires a convincing clinical history of immediate allergic symptoms upon ingestion OR a positive medical food challenge . Performing broad, unprompted screening panels in the absence of clinical symptoms is poor practice and leads to unnecessary, harmful dietary restrictions.
Peanut Oral Immunotherapy (OIT)
Oral Immunotherapy (OIT)—exemplified by standardized defatted peanut flour (Palforzia), authorised in the EU for children aged 1 to 17 years—represents an established disease-modifying intervention for IgE-mediated peanut allergy.
Clinical Protocol : Comprises an initial escalating dose day under continuous specialist supervision in a resuscitation-equipped facility, followed by biweekly up-dosing over several months, reaching a continuous daily maintenance dose (typically 300 mg of peanut protein, equivalent to approximately one peanut kernel).
Mechanism and Clinical Goal : OIT raises the patient's reaction threshold (clinical desensitization ) during maintained treatment, reducing risk from accidental exposure; anaphylaxis can still occur.
Critical Limitations & Risks : OIT does not cure the allergy and rarely induces unmaintained tolerance (permanent tolerance). If the patient halts daily consumption, the desensitized state is rapidly lost within days or weeks. Furthermore, OIT carries an ongoing risk of systemic allergic reactions (requiring adrenaline in up to 10–15% of patients) and predisposes to Eosinophilic Esophagitis (EoE) . All patients on OIT must continue to practice dietary avoidance of unmeasured peanut products and carry two adrenaline auto-injectors at all times .